These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35688145)

  • 1. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes.
    Dobosh B; Zandi K; Giraldo DM; Goh SL; Musall K; Aldeco M; LeCher J; Giacalone VD; Yang J; Eddins DJ; Bhasin M; Ghosn E; Sukhatme V; Schinazi RF; Tirouvanziam R
    Cell Rep; 2022 Jun; 39(11):110945. PubMed ID: 35688145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
    Hoang TN; Pino M; Boddapati AK; Viox EG; Starke CE; Upadhyay AA; Gumber S; Nekorchuk M; Busman-Sahay K; Strongin Z; Harper JL; Tharp GK; Pellegrini KL; Kirejczyk S; Zandi K; Tao S; Horton TR; Beagle EN; Mahar EA; Lee MYH; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Delmas OM; Wang S; Cooney KA; Sayegh MN; Wang L; Filev PD; Weiskopf D; Silvestri G; Waggoner J; Piantadosi A; Kasturi SP; Al-Shakhshir H; Ribeiro SP; Sekaly RP; Levit RD; Estes JD; Vanderford TH; Schinazi RF; Bosinger SE; Paiardini M
    Cell; 2021 Jan; 184(2):460-475.e21. PubMed ID: 33278358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
    Solimani F; Meier K; Ghoreschi K
    Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
    Jorgensen SCJ; Tse CLY; Burry L; Dresser LD
    Pharmacotherapy; 2020 Aug; 40(8):843-856. PubMed ID: 32542785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice.
    Sakai H; Kamuro H; Tokunoh N; Izawa T; Tamiya S; Yamamoto A; Tanaka S; Okuzaki D; Ono C; Matsuura Y; Okada Y; Yoshioka Y; Fujio Y; Obana M
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F931-F941. PubMed ID: 38634132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
    Akbarzadeh-Khiavi M; Torabi M; Rahbarnia L; Safary A
    Infection; 2022 Apr; 50(2):295-308. PubMed ID: 34902115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
    Rodriguez-Garcia JL; Sanchez-Nievas G; Arevalo-Serrano J; Garcia-Gomez C; Jimenez-Vizuete JM; Martinez-Alfaro E
    Rheumatology (Oxford); 2021 Jan; 60(1):399-407. PubMed ID: 33020836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.
    Gáspár Z; Szabó BG; Andrikovics H; Ceglédi A; Rajmon M; Ábrahám A; Várnai Z; Kiss-Dala N; Szlávik J; Sinkó J; Vályi-Nagy I; Lakatos B
    Geroscience; 2024 Jun; 46(3):2863-2877. PubMed ID: 38367195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
    Stebbing J; Sánchez Nievas G; Falcone M; Youhanna S; Richardson P; Ottaviani S; Shen JX; Sommerauer C; Tiseo G; Ghiadoni L; Virdis A; Monzani F; Rizos LR; Forfori F; Avendaño Céspedes A; De Marco S; Carrozzi L; Lena F; Sánchez-Jurado PM; Lacerenza LG; Cesira N; Caldevilla Bernardo D; Perrella A; Niccoli L; Méndez LS; Matarrese D; Goletti D; Tan YJ; Monteil V; Dranitsaris G; Cantini F; Farcomeni A; Dutta S; Burley SK; Zhang H; Pistello M; Li W; Romero MM; Andrés Pretel F; Simón-Talero RS; García-Molina R; Kutter C; Felce JH; Nizami ZF; Miklosi AG; Penninger JM; Menichetti F; Mirazimi A; Abizanda P; Lauschke VM
    Sci Adv; 2021 Jan; 7(1):. PubMed ID: 33187978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
    Paules CI; Wang J; Tomashek KM; Bonnett T; Singh K; Marconi VC; Davey RT; Lye DC; Dodd LE; Yang OO; Benson CA; Deye GA; Doernberg SB; Hynes NA; Grossberg R; Wolfe CR; Nayak SU; Short WR; Voell J; Potter GE; Rapaka RR
    Ann Intern Med; 2024 Mar; 177(3):343-352. PubMed ID: 38408357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CCR2 Signaling Restricts SARS-CoV-2 Infection.
    Vanderheiden A; Thomas J; Soung AL; Davis-Gardner ME; Floyd K; Jin F; Cowan DA; Pellegrini K; Shi PY; Grakoui A; Klein RS; Bosinger SE; Kohlmeier JE; Menachery VD; Suthar MS
    mBio; 2021 Dec; 12(6):e0274921. PubMed ID: 34749524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
    Bronte V; Ugel S; Tinazzi E; Vella A; De Sanctis F; Canè S; Batani V; Trovato R; Fiore A; Petrova V; Hofer F; Barouni RM; Musiu C; Caligola S; Pinton L; Torroni L; Polati E; Donadello K; Friso S; Pizzolo F; Iezzi M; Facciotti F; Pelicci PG; Righetti D; Bazzoni P; Rampudda M; Comel A; Mosaner W; Lunardi C; Olivieri O
    J Clin Invest; 2020 Dec; 130(12):6409-6416. PubMed ID: 32809969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
    Praveen D; Puvvada RC; M VA
    Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
    Titanji BK; Farley MM; Mehta A; Connor-Schuler R; Moanna A; Cribbs SK; O'Shea J; DeSilva K; Chan B; Edwards A; Gavegnano C; Schinazi RF; Marconi VC
    Clin Infect Dis; 2021 Apr; 72(7):1247-1250. PubMed ID: 32597466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
    Petrone L; Petruccioli E; Alonzi T; Vanini V; Cuzzi G; Najafi Fard S; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Grifoni A; Antinori A; Vergori A; Ippolito G; Cantini F; Goletti D
    J Infect; 2021 Apr; 82(4):58-66. PubMed ID: 33639176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.
    Tanimoto T; Tada S; Fujita S; Hirakawa T; Matsumura M; Isoyama S; Ueno S; Hamai K; Tsuji N; Hirosawa H; Taniguchi T; Okamoto T; Omoto T; Kusunoki S; Maeda H; Ishikawa N
    Respir Investig; 2022 May; 60(3):418-424. PubMed ID: 35307364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.